Actelion Revenue and Competitors

Actelion Ltd is a Swiss biopharmaceutical company that focuses on the discovery and development of treatments to serve unmet medical needs. Its products specialize in conditions related to the endothelium. The Company has three approved drugs on the market. Tracleer, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension, a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. Ventavis is an inhaled formulation of iloprost, a synthetic analogue of prostacyclin PGI2 that dilates systemic and pulmonary arterial vascular beds. It also affects platelet aggregation. The third drug, Zavesca, was in-licensed from Oxford GlycoSciences. Zavesca is an approved oral treatment for type 1 Gaucher disease, a rare debilitating metabolic disorder. In addition, the Company was evaluating nine compounds in various phases of clinical development in 2007.